Thrombotic events in critically ill children with coronavirus disease 2019 or multisystem inflammatory syndrome in children

Aleksandra S. Dain, Leslie Raffini, and Hilary Whitworth

Purpose of review
To provide an update regarding what is known about thrombotic events and thromboprophylaxis in critically ill children with SARS-CoV-2 infection.

Recent findings
Pediatric patients with SARS-CoV-2 generally have mild illness; however, intensive care is required in about 20–30% of hospitalized children with COVID-19 and an even higher proportion in those with MIS-C. Increased rates of thrombosis have been observed in adults hospitalized with COVID-19, and clinical trials have attempted to optimize thromboprophylaxis. There is significant variability in the estimated incidence of thrombosis in pediatric patients (0–27%) because of variation in patient populations and study design. Multiple studies demonstrate an increased rate of thrombosis compared with baseline in hospitalized pediatric patients. Few studies have evaluated risk factors for thrombosis, but critical illness, older age, and other known thrombosis risk factors appear to increase the risk. Thromboprophylaxis strategies are inconsistent, with little evidence of efficacy but few reports of major bleeding.

Summary
Critically ill children with SARS-CoV-2-related illnesses are at increased risk of thrombosis. Thromboprophylaxis should be considered in select patients with COVID-19 or MIS-C, though the optimal strategy is not yet known. More data is required to guide practice to prevent thrombosis in this population.

Keywords
COVID-19, MIS-C, pediatrics, thromboprophylaxis, thrombosis

INTRODUCTION
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) continues to spread worldwide, causing the ongoing coronavirus-19 (COVID-19) pandemic. Early in the pandemic, it became evident that adults hospitalized with COVID-19 had increased rates of thrombosis leading to worse outcomes [1,2]. Although most children infected with SARS-CoV-2 have mild symptoms, some experience severe illness and death [3,4,5,6]. Children are also uniquely at risk for the postinfectious multisystem inflammatory syndrome in children (MIS-C). MIS-C is defined by multiorgan involvement, laboratory markers of inflammation, fever, severe illness, and evidence of a recent SARS-CoV-2 infection [7]. As the pandemic evolved, reports describing increased rates of venous and arterial thrombotic events in children with COVID-19 and MIS-C emerged. Children hospitalized with COVID-19 or MIS-C often have other known risk factors for thrombosis including critical illness, central venous catheters (CVCs), or prothrombotic comorbidities, further increasing their risk for thrombotic events. In this review, we discuss the current understanding of thrombosis in children with SARS-CoV-2-associated illnesses, focused on critically ill children and adolescents. Wherever relevant, we also discuss adult studies. This is an evolving area of research and clinical practice, and we anticipate emerging data may lead to additional insights and recommendations.
SEVERITY OF SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS-2 INFECTION IN CHILDREN

As of 27 January 2022, the American Academy of Pediatrics and the Children’s Hospital Association estimate 11,411,047 children have been infected with SARS-CoV-2, representing 18.6% of all cases [8*]. Children with prior comorbidities are more likely to develop severe disease and have a higher risk of death from COVID-19 [6*,9*]. In one cross sectional study of 713 children hospitalized with acute COVID-19 (July through August 2021), 29.5% were admitted to the ICU; and 1.5% died [9*]. A majority had at least one underlying medical condition, the most common being obesity, asthma or reactive airway disease, and feeding tube dependence [9*]. Children with underlying medical problems and adolescents were admitted to the ICU at higher rates than younger children and those without comorbidities [9*]. Two large database studies reported similar ICU admission rates of 21–29.6% in children hospitalized primarily with COVID-19 [5*,10]. Children hospitalized with MIS-C have an even higher ICU admission rate (58.2–73.8%) [11**,12].

SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS-2-INDUCED COAGULOPATHY

The primary inciting factor for hypercoagulability in SARS-CoV-2 infection is thought to be direct and indirect endothelial damage by viral infection and systematic inflammation, leading to activation of tissue factor pathways, platelets, and multiple cytokines [13*,14]. Elevated D-dimer is the most common laboratory abnormality, though its prognostic ability is unclear in pediatric thrombotic events [13*,15*,16,17]. Prolonged prothrombin time, elevated fibrinogen, and thrombocytopenia are also markers of SARS-CoV-2 coagulopathy [15*,18*,19]. Consumptive coagulopathy and disseminated intravascular coagulopathy may be seen in critically ill patients and may increase bleeding risk [18*].

Ongoing research in MIS-C has also demonstrated alterations in the inflammatory cascade and hemostasis [11**,20]. Little is known about the cause of thrombosis in MIS-C, though the mechanism is thought to be similar to that in acute COVID-19 [13*].

THROMBOTIC COMPLICATIONS AND THROMBOPROPHYLAXIS IN ADULTS WITH CORONAVIRUS DISEASE 2019

The estimated prevalence of thrombosis in hospitalized adults with COVID-19 has varied widely because of changes in clinical guidelines and variation in study design. A Cochrane review reports a weighted mean incidence of venous thromboembolism (VTE) in hospitalized adults of 7.4% with a range of 0–46.2% in the included studies [1*]. This incidence is higher for critically ill adults with COVID-19 [21]. Furthermore, adult patients who develop thrombotic events have a worse prognosis [2]. A similar pooled incidence of VTE was found even when studies were categorized by thromboprophylaxis strategy, indicating that thrombotic events occur despite thromboprophylaxis [21]. These data drove the development of multiple clinical trials evaluating the utility and dose intensity of thromboprophylaxis in adults with COVID-19.

Three international, adaptive, randomized clinical trials (REMAP-CAP, ACTIV-4a, and ATTAC) were coordinated in a multiplatform design to evaluate therapeutic dose unfractionated or low-molecular-weight heparin (LMWH), compared with standard care (prophylactic or intermediate dose) in hospitalized adults [22*]. Several anticoagulant regimens were allowed in these trials with dosing that varied with morbid obesity or abnormal renal function. In general, for enoxaparin, the most common LMWH in children, therapeutic dosing was 1 mg/kg twice daily or 1.5 mg/kg daily, prophylactic dosing was 40 mg daily, and intermediate dosing was 0.5 mg/kg twice daily [22*]. In the subset of critically ill adults, there was no benefit in primary outcome (median organ support-free days) in patients receiving therapeutic anticoagulation [22*]. Fewer patients receiving therapeutic dose had major thrombotic events compared with those receiving usual care (6.4 versus 10.4%); however, the combined outcome of major thrombotic events and death was similar [22*]. Major bleeding was higher in the therapeutic arm (3.8 versus 2.3%), though this difference was not statistically significant [22*]. Similarly, there was no
benefit of intermediate dose compared with prophylactic dose enoxaparin in the randomized controlled INSPIRATION trial that included 562 critically ill adults [23].

In contrast to the lack of benefit of therapeutic (compared with standard) intensity anticoagulation in critically ill adults with COVID-19, results from several trials suggest that there is a potential benefit in hospitalized, non-ICU patients [24–26]. The 2021 American Society of Hematology guidelines suggest prophylactic over intermediate intensity anticoagulation for thromboprophylaxis in critically ill patients with COVID-19 (conditional recommendation 1A) [27**]. The 2022 National Institutes of Health guidelines strongly recommend prophylactic dose heparin thromboprophylaxis in critically ill adults (strong recommendation, level AI) and recommend against intermediate or therapeutic dose anticoagulation for this indication (moderate recommendation, level BI) [28**]. Elevated D-dimer has been associated with disease severity and thrombosis but it is a nonspecific marker. Current adult guidelines do not alter thromboprophylaxis strategies in critically ill patients based on D-dimer levels [27**].

THROMBOTIC EVENTS IN CHILDREN WITH CORONAVIRUS DISEASE 2019 OR MULTISYSTEM INFLAMMATORY SYNDROME IN CHILDREN

Data on thrombotic complications in children with SARS-CoV-2-associated illnesses include case reports, case series, and multicenter cohort studies. These studies report variable rates of thrombosis, but overall, there is a much lower incidence of thrombosis in children compared with adults hospitalized with COVID-19. Interpretation of pediatric data on SARS-CoV-2 and thrombotic events has many limitations. Several studies have combined venous and arterial thrombosis as well as patients with COVID-19 and MIS-C, and many have not separately reported critically ill children. Furthermore, large studies evaluating children with COVID-19 or MIS-C may not have included thrombotic events as a specific outcome, or may have included only certain thrombotic events (stroke, VTE) with limited descriptions of the events [9*,10,12]. Select case-series and cohort studies are summarized in Table 1.

In a United States, multicenter, retrospective cohort study of 814 consecutive pediatric patients hospitalized with SARS-CoV-2-associated illness from March through August 2020, the incidence of venous and arterial thrombotic events was 0.7% in patients with asymptomatic SARS-CoV-2, 2.1% in patients with COVID-19, and 6.5% in MIS-C [17*]. In this cohort, 32% of children with COVID-19 and 62% of children with MIS-C required ICU admission [17*]. Most patients with thrombotic events (72%) were admitted to the ICU, compared with 38% of patients without thrombosis [17*]. The development of thrombotic events was associated with older age (≥12 years), the presence of a CVC, cancer, and MIS-C [17*]. The highest rate of thrombosis (19%, 9/48) was observed in patients with MIS-C who were at least 12 years of age [17*]. Of the 19 thrombotic events in patients with symptomatic COVID-19 or MIS-C, there were 11 deep vein thromboses (DVT), 3 pulmonary embolisms (PE), 3 intracardiac thromboses, 1 acute ischemic stroke, and 1 cerebral sinus venous thrombosis [17*]. The mortality in patients with COVID-19 or MIS-C with thrombotic events in this cohort was 28% (5/18), which mirrors adult data that demonstrate thrombosis is associated with worse prognosis in COVID-19 [2,17*]. A multicenter study from Egypt reported lower extremity DVT in 5/394 (1.3%) of children with COVID-19 [29*]. Although the age of the patients with DVT was not reported, none were critically ill [29*]. Elevated D-dimer was associated with DVT in this cohort [29*].

The Overcoming COVID-19 Network, a large multicenter registry, observed DVT or pulmonary embolism in 11/539 (2%) patients with MIS-C and 8/577 (1%) patients with severe acute COVID-19 [11*]. Details about patients with DVT/PE were not reported, although four patients with MIS-C were previously published, and in that report, three of four thrombotic events occurred in patients at least 13 years of age [30*]. A subsequent report from this network reported 12 of 1695 (0.7%) ischemic or hemorrhagic strokes [31*]. Many of these patients had underlying risk factors for stroke [31*]. The cause of SARS-CoV-2-associated neurologic disease, including stroke, is unclear and likely multifactorial but neuroinflammation may play a role [31*,32*,33].

Mitchell et al. [34*] reported the highest rate of thrombotic complications (7/27, 26%) in a single center study of hospitalized pediatric patients with symptomatic COVID-19 in New York. There were three DVT and four PE, and three of seven patients were older than 12 years [34*]. A majority (59%) were critically ill, and increased ventilatory support was associated with thrombosis [34*]. Four (57%) of the seven patients with thrombotic events received prophylaxis prior to developing thrombosis [34*].

Notably, some studies report much lower thrombosis rates. Antoon et al. [5*] reports thrombotic complications in 0.4% (18/4063) of patients with either MIS-C or acute COVID-19 in a multicenter administrative database, and there were no thrombotic complications in three single-center,
smaller studies of 33–56 patients admitted with SARS-CoV-2-associated illnesses [15*,35*,36*].

Cases of cerebral infarcts as well as venous and cardiac thrombosis have been reported in children requiring extracorporeal membrane oxygenation (ECMO) for COVID-19 or MIS-C [31*,37*,38–40]. Adult studies have reported an increased risk of venous, arterial, and circuit thrombosis in patients requiring ECMO for COVID-19 [41,42]. No large studies have evaluated whether pediatric patients on ECMO with SARS-CoV-2-related illness are at increased risk of thrombosis.

The variable rates of thrombosis reported in children with COVID-19 and MIS-C (0–27%) are likely related to differences in study population (age, underlying medical condition, critical illness), and possibly because of variation in thromboprophylaxis strategies [5*,11*,15*,17*,29*,34*–36*]. There are differences in how thrombosis was identified, including administrative data codes, imaging findings, or clinician reports. Despite the variation in studies, critically ill children, especially adolescents, with COVID-19 or MIS-C appear to have an increased incidence of thrombosis compared with baseline VTE incidence in critically ill children (7.4 per 1000) [43].

### Table 1. Thrombosis in select studies of hospitalized children with severe acute respiratory syndrome coronavirus-2-associated illnesses

| Author                  | COVID-19 (n) | MIS-C (n) | Critically ill (%) | Thrombosis COVID-19 [n (%)] | Anticoagulation COVID-19 [n (%)] | Anticoagulation MIS-C [n (%)] | Location | Type of thrombotic event |
|-------------------------|-------------|-----------|--------------------|------------------------------|----------------------------------|-------------------------------|----------|--------------------------|
| Mitchell et al. [34*]   | 27          | 0         | 59%                | 7 (26)                       | N/A                              | 11 (41)                       | N/A      | Portal vein [1], U [1], PE [4], DVT [1] |
| Whitworth et al. [17*]  | 426         | 138       | 39%                | 9 (2.1)                      | 9 (6.5)                          | 128 (30)                      | United States [multicenter]   | DVT [11], PE [3], Intracardiac [3], AIS [1], CSVT [1] |
| Del Borrello et al. [36*] | 30          | 6         | 11%                | 0                            | 4 (13)                           | 2 (33)                        | Turin, Italy | N/A |
| Leeman et al. [15*]    | 47          | 9         | 27%                | 0                            | 16 (29)                          |                                | Miami, FL, United States | N/A |
| Capone et al. [35*]    | 0           | 33        | 79%                | N/A                          | 0                                | NR                            | New York, NY, United States | N/A |
| Feldstein et al. [11**] | 577         | 539       | 58%                | 8 (1)                        | 11 (2)                           | 162 (28)                      | United States [multicenter]   | DVT or PE |
| Antoon et al.* [5*]    | 3720        | 343b      | 21%                | 18 (0.4)                     | NR                              | United States [multicenter]   | NR |
| Saleh et al. [29*]     | 394         | 4         | 26%                | 5 (1.3)                      | NR                              | Egypt [multicenter]           | DVT |
| Beslow et al. [32*]    | 971         | NR        |                    | 8 (0.82)                     | NR                              | International [multicenter]   | AIS [7], CSVT [1] |

AIS, arterial ischemic stroke; COVID-19, coronavirus disease 19; CSVT, cerebral sinovenous thrombosis; DVT, deep vein thrombosis; IJ, internal jugular; MIS-C, multisystem inflammatory syndrome in children; N/A, not applicable; NR, not reported; PE, pulmonary embolism.

*Administrative database study.

**Included patients with Kawasaki disease or MIS-C.

*Study only evaluated for ischemic stroke. Included any patient hospitalized with positive SARS-CoV-2 test and did not differentiate between MIS-C, acute COVID-19, or asymptomatic SARS-CoV2 infection. Represents a combination of COVID-19 and MIS-C.

**Emergency and critical care medicine**

**THROMBOPROPHYLAXIS IN CHILDREN WITH CORONAVIRUS DISEASE 2019 AND MULTISYSTEM INFLAMMATORY SYNDROME IN CHILDREN**

Similar to reports of thrombotic events occurring despite pharmacologic thromboprophylaxis in adult cohorts, many of the thrombotic events in the pediatric studies occurred despite thromboprophylaxis [17*,34*,44,45]. Early in the pandemic, pediatric hematology and critical care experts organized consensus guidelines for thromboprophylaxis in children hospitalized with COVID-19 or MIS-C, based largely on expert opinion and extrapolation of adult data [46**]. The guidelines suggest thromboprophylaxis with low-dose LMWH targeting an anti-Xa activity of 0.2 to less than 0.5 units/ml for children hospitalized with COVID-19 or MIS-C who have additional VTE risk factors (CVC, mechanical ventilation, obesity, malignancy, cardiac disease, etc.) or who have
D-dimer at least five times the upper limit of normal, unless there are contraindications to anticoagulation [46*]. Anticoagulant prophylaxis was not recommended for children with asymptomatic SARS-CoV-2 infection who are hospitalized for other causes, unless there are other VTE risk factors present [46*]. Importantly, these guidelines were developed prior to adult thromboprophylaxis trials and most of the pediatric studies looking at incidence and risk factors. Elevated D-dimer was associated with thrombotic events in some pediatric studies but its use as a predictor of thrombosis is limited because of the variation in timing and frequency of testing [17*,29*]. Furthermore, adult thromboprophylaxis guidelines do not recommend dose titration in critically ill patients based on D-dimer levels [27**,28**]. It is important to consider these limitations and new data when interpreting the pediatric guidelines.

Individual institutions have adjusted the pediatric recommendations based on the new epidemiologic data and adult thromboprophylaxis trials described above. The Children’s Hospital of Philadelphia guidelines, which are publicly available, recommend enoxaparin every 12 hours, targeting an anti-Xa of 0.2–0.4 units/ml (in the absence of contraindications) in critically ill children with COVID-19 at least 12 years of age and those less than 12 years if the child requires intubation and/or a CVC [47]. For MIS-C, we recommend enoxaparin every 12 hours targeting an anti-Xa of 0.2–0.4 units/ml in patients at least 12 years and low-dose aspirin for those less than 12 years, after assessing for contraindications [48]. Of note, enoxaparin is not approved by the US Food and Drug Administration for use in children. As there are no pediatric-specific SARS-CoV-2 thromboprophylaxis trials focused on efficacy, this dosing strategy is based on expert opinion. Twice daily dosing is consistent with prophylactic intensity in children but would be considered intermediate intensity in adults, for whom prophylactic intensity is typically once daily dosing [27**,49]. For patients older than 18 years of age cared for in pediatric centers, it is reasonable to follow adult guidelines, which are based on high-quality, randomized controlled trial data [27**,28**].

The COVID-19 Anticoagulation in Children – Thromboprophylaxis (COVAC-TP) trial is the only pediatric study evaluating the safety of thromboprophylaxis in children [50]. This study evaluated the safety of low dose LMWH targeting an anti-Xa level of 0.2–0.49 IU/mL in 38 children. There were no clinically relevant bleeding events. Efficacy was an exploratory outcome and two children (5.3%) developed VTE [50].

**Antiplatelet therapy in multisystem inflammatory syndrome in children**

Low-dose aspirin is recommended by the American College of Rheumatology for children with MIS-C until normalization of the platelet count and confirmed normal coronary arteries at least 4 weeks after diagnosis [51*]. The addition of anticoagulation in select MIS-C patients with cardiac involvement is recommended and the authors suggest an individualized approach to anticoagulation in the absence of cardiac involvement, depending on additional patient risk factors for bleeding and thrombosis [51*].

**BLEEDING IN CHILDREN WITH CORONAVIRUS DISEASE 2019 AND MULTISYSTEM INFLAMMATORY SYNDROME IN CHILDREN**

Data on bleeding in pediatrics is primarily restricted to case reports [31*,52–56]. One cohort study reports major bleeding in 1.6% of COVID-19 and 2.4% of MIS-C admissions; about half (4/9) occurred on anticoagulation [17*]. Bleeding in adults is associated with therapeutic anticoagulation and is particularly increased in patients receiving ECMO [18*,21]. Major bleeding appears uncommon overall in pediatrics, despite the use of prophylactic anticoagulation in hospitalized patients as well as aspirin in MIS-C.

**THROMBOSIS TREATMENT**

Thrombotic events in pediatric patients with COVID-19 or MIS-C are considered provoked and treated as such, typically with therapeutic anticoagulation for 6 weeks to 3 months [57,58*]. Critically ill patients are at higher risk for bleeding and, in line with adult guidelines, we recommend initial unfractionated heparin or LMWH over direct oral anticoagulants [59].

**CONCLUSION**

Pediatric data are limited and vary significantly in their findings. However, there appears to be an increased rate of thrombotic complications in critically ill children with COVID-19 or MIS-C, even when compared with other critically ill children. Children with thrombotic complications may have worse outcomes but often have co-existing morbidities that likely contribute [17*]. Thromboprophylaxis appears well tolerated in pediatrics and should be strongly considered in critically ill children with COVID-19 or MIS-C, many of whom have multiple...
Emergency and critical care medicine

risk factors for thrombosis. Optimal intensity of anticoagulation in this population has not been determined. Carefully designed prospective studies focused on thrombogenic and hemorrhagic complications in hospitalized children with SARS-CoV2-related illness are needed to better inform current management strategies and improve outcomes.

Acknowledgements

None.

Financial support and sponsorship

This work was supported by the National Institutes of Health, National Heart, Lung and Blood Institute T32 HL0007150-45 (A.S.D.) and T32 HL007971 (H.W.).

Conflicts of interest

There are no conflicts of interest.

REFERENCES AND RECOMMENDED READING

Papers of particular interest, published within the annual period of review, have been highlighted as:

* of special interest
** of outstanding interest

1. Pellicori P, Duboi G, Wong CM, et al. COVID-19 and its cardiovascular effects: a systematic review of prevalence studies. Cochrane database Syst Rev 2021; 3:CD013879.

   This systematic review calculates the pooled incidence of VTE in hospitalized adults with COVID-19 and summarizes many prior studies that attempted to define incidence and risk factors for VTE with COVID-19.

2. Malas MB, Naazie IN, Elsayed N, et al. Thromboembolism risk of COVID-19 is high and associated with a higher risk of mortality: a systematic review and meta-analysis. EClinicalMedicine 2020; 29–30.

3. Li B, Zhang S, Zhang R, et al. Epidemiological and clinical characteristics of COVID-19 in children: a systematic review and meta-analysis. Front Pediatr 2020; 8:1–12.

4. Jurado Hernández JL, Álvarez Orozco IF. COVID-19 in children: respiratory involvement and some differences with the adults. Front Pediatr 2021; 9:622404.

5. Antoon JW, Grijalva CG, Thur C, et al. Factors associated with COVID-19 disease severity in US children and adolescents. J Hosp Med 2021; 16:803–810.

   This large retrospective cohort study from U.S. children’s hospitals evaluates disease severity in hospitalized and nonhospitalized children with SARS-CoV-2 infection. This study is unique in that it uses administrative data and includes patients discharged from emergency departments in addition to hospitalized children.

6. Tsankov BK, Allaire JM, Irvine MA, et al. Severe COVID-19 infection and pediatric comorbidities: a systematic review and meta-analysis. Int J Infect Dis 2021; 103:246–256.

   This systematic review and meta-analysis evaluates the effect of comorbidities on the severity of COVID-19 in pediatric patients by assessing the rate of ICU admission and mortality.

7. CDC. Information for Healthcare Providers about Multisystem Inflammatory Syndrome (MIS-C) [Internet]. Centers for Disease Control and Prevention. 2020 [updated 4 May 2021]. Available at: https://www.cdc.gov/mis-c/hcp/index.html. [Accessed 4 February 2022]

   American Academy of Pediatrics. Children and COVID-19: State-Level Data. [Report [Internet], [updated 31 January 2022]. Available at: http://www.aap.org/en/pages/2019-novel-coronavirus-covid-19-infections/childrenandcovid-19-state-level-data-report/. [Accessed 4 February 2022]

   This website provides up-to-date epidemiologic data on pediatric SARS-CoV-2 infections in the United States.

9. Wang V, Gerdies ME, Shi DS, et al. Characteristics and clinical outcomes of children and adolescents aged <18 years hospitalized with COVID-19 – six hospitals, United States, July-August. MMWR Morb Mortal Wkly Rep 2021; 70:1766–1772.

   This recently published MMWR report describes clinical characteristics and outcomes of hospitalized children during the peak of the SARS-CoV-2 Delta variant in the United States.

10. Komarjets L, Agarhis NT, Nelson JM, et al. Underlying medical conditions associated with severe COVID-19 illness among children. JAMA Netw Open 2021; 4:e2111182.

11. Feldstein LR, Tenforde MW, Friedman KG, et al. Overcoming COVID-19 Investigators. Characteristics and outcomes of US children and adolescents with multisystem inflammatory syndrome in children (MIS-C) compared with severe acute COVID-19. JAMA 2021; 325:1074–1087.

   This large, multicenter case series from the Overcoming COVID-19 Investigators evaluates characteristics and outcomes associated with MIS-C compared to severe COVID-19 in hospitalized pediatric patients. There is significant detail about characteristics to differentiate patients with MIS-C and COVID-19.

12. Belay ED, Abrams J, Oster ME, et al. Trends in geographic and temporal distribution of US children with multisystem inflammatory syndrome during the COVID-19 pandemic. JAMA Pediatr 2021; 175:837–845.

13. Tran VL, Parsons S, Varela CR. The trilogy of SARS-CoV-2 infections [part 3]: thrombosis, anticoagulant, and antiplatelet considerations. J Pediatr Pharmacol Ther 2021; 26:565–576.

   This review is one of a three-part series about SARS-CoV-2 infection in pediatric patients. Tran et al. summarize SARS-CoV-2 associated coagulopathy and thrombosis, risk factors for VTE, and guidelines for anticoagulation dosing.

14. Hotel L, Deeb AP, Andraska EA, et al. The pathobiological basis for thrombotic complications in COVID-19: a review of the literature. Curr Pathobiol Rep 2021; 9:107–117.

15. Leeman R, Shaog J, Borchetta M, et al. Clinical implications of hematologic and hemostatic abnormalities in children with COVID-19. J Pediatr Hematol Oncol 2022; 44:ES28–ES28.

   This single-center study evaluates hematologic changes, including thrombosis, in children hospitalized with COVID-19.

16. Loi M, Branchford B, Kim J, et al. COVID-19 anticoagulation recommendations in children. Pediatr Blood Cancer 2020; 67:17–19.

17. Whitworth HB, Sartain SE, Kumar R, et al. Rate of thrombosis in children and adolescents hospitalized with COVID-19 or MIS-C. Blood 2021; 138:190–198.

   This large cohort study of pediatric patients with SARS-CoV-2 infection reports the rate of thrombosis in hospitalized children with asymptomatic SARS-CoV-2, symptomatic COVID-19, and MIS-C and clinical characteristics associated with thrombotic events. The authors also report patient outcomes and thromboprophylaxis patterns.

18. Gerber GF, Chaturvedi S. How to recognize and manage COVID-19-associated coagulopathy. Hematol Am Soc Hematol Educ Progr 2021; 2021:614–620.

   This educational publication from the American Society of Hematology describes COVID-19-associated coagulopathy in adults and provides recommendations for management of coagulopathy and bleeding. There is also a summary of vaccine-induced thrombotic thrombocytopenia.

19. Zaffanella M, Piacentini G, Nisetoi L, et al. Thrombosis in children with COVID-19 infection: a systematic review of the literature. Tromb Res 2021; 205:92–98.

20. Al-Ghafry M, Vagrecha A, Malik M, et al. Multisystem inflammatory syndrome in children (MIS-C) and the prothrombotic state: coagulation profiles and rotational thromboelastometry in a MIS-C cohort. J Thromb Haemost 2021; 19:1764–1770.

21. Jimenez D, Garcia-Sanchez A, Raip P, et al. Incidence of VTE and bleeding among hospitalized patients with coronavirus disease. Chest 2021; 159:1182–1196.

22. REMAP-CAP Investigators, ACTIV-4a Investigators, ATTACC Investigators. Gerlicher EC, Bradbury CA, et al. Therapeutic anticoagulation with heparin in critically ill patients with COVID-19. N Engl J Med 2021; 385:777–789.

   This multiplatform, randomized clinical trial of anticoagulation dose intensity in critically ill adults with COVID-19 compares therapeutic dose heparin to usual care (prophylactic or intermediate dose). These results inform clinical practice guidelines for thromboprophylaxis in adults.

23. INSPIRATION Investigators, Sadeghipour P, Talasaz AH, et al. Effect of intermediate-dose vs standard-dose prophylactic anticoagulation on thrombotic events, extracorporeal membrane oxygenation treatment, or mortality among patients with COVID-19 admitted to the intensive care unit: the INSPIRATION Randomized Clinical Trial. JAMA 2021; 325:1620–1630.

   This large, randomized clinical trial compares prophylactic to intermediate dose anticoagulation for thromboprophylaxis in critically ill adults with COVID-19. These results inform adult thromboprophylaxis guidelines.

24. ATTACC Investigators, ACTIV-4a Investigators, REMAP-CAP Investigators, Lawler PR, Goligher EC, et al. Therapeutic anticoagulation with heparin in noncritically ill patients with COVID-19. N Engl J Med 2021; 385:790–802.

   This single-center, randomized comparison of therapeutic vs prophylactic or intermediate-dose heparins for thromboprophylaxis in critically ill adults with COVID-19 provided important information about clinical practice and guidelines for thromboprophylaxis.
COVID-19 pediatric patient: a successful outcome. ASAIO J 2021; 67:250–253.

41. Weir-McCall JR, Gales G, Mun Mak S, et al. Vascular Thrombosis in Severe COVID-19: Requiring Extracorporeal Membrane Oxygenation: A Multicenter Study. Crit Care Med 2022; 50:624–632.

42. Bemtgen X, Zottmann V, Benk C, et al. Thrombotic circuit complications during venovenous extracorporeal membrane oxygenation in COVID-19. J Thorb Thrombol 2021; 51:301–307.

43. Higginson RA, Lawson KA, Christie LM, et al. National Association of Children’s Hospitals and Related Institution’s Pediatric Intensive Care Unit FOCUS group. Incidence and risk factors associated with venous thrombotic events in pediatric intensive care unit patients. Pediatr Crit Care Med 2011; 12:e28–e34.

44. Liistro JF, Leclerc M, Choochoo C, et al. High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients. J Thorb Haemost 2020; 18:1743–1746.

45. Middelberg S, Goppens M, van Haas PF, et al. Incidence of venous thromboembolism in hospitalized patients with COVID-19. J Thorb Haemost 2020; 18:1995–2002.

46. Goldenberg NA, Sochet A, Albisetti M, et al. Consensus-based clinical recommendations and research priorities for anticoagulant thromboprophylaxis in children hospitalized for COVID-19–related illnesses. J Thorb Haemost 2020; 18:3099–3105.

These were the first published guidelines to address thromboprophylaxis in pediatric patients with COVID-19 and MIS-C. They describe risk factors for thrombosis, criteria and dosing for thromboprophylaxis, and recommendations for future research priorities.

47. Chiotos K, Davis D, Kerman C, et al. Clinical pathway for evaluation and treatment of patients with active COVID-19 infection [Internet]. Philadelphia (PA): Children’s Hospital of Philadelphia, [Updated February 2022]. Available at: https://www.chop.edu/clinical-pathway/covid-disease-clinical-pathway. [Accessed 4 February 2022]

48. Chiotos K, Corwin D, Santori L, et al. Emergency Department, ICU and Inpatient Clinical Pathway for Evaluation of Possible Multisystem Inflammatory Syndrome (MIS-C) [Internet]. Philadelphia (PA): Children’s Hospital of Philadelphia, [Updated 2021 July]. Available at: https://www.chop.edu/clinical-pathway/multisystem-inflammatory-syndrome-mis-c-clinical-pathway. [Accessed 4 February 2022]

49. O’Brien SH, Lee H, Ritchey AK. Once-daily enoxaparin in pediatric thromboembolism: a dose finding and pharmacodynamics/pharmacokinetics study. J Thorb Haemost 2007; 5:1985–1987.

50. Sochet AA, Morrison JM, Jaffry J, et al. Enoxaparin Thromboprophylaxis in Children Hospitalized for COVID-19: A Phase 2 Trial. Pediatrics 2022; https://doi.org/10.1542/peds.2022-056726.

51. Henderson LA, Canna SW, Friedman KG, et al. American College of Rheumatology clinical guidance for multisystem inflammatory syndrome in children associated with SARS-CoV-2 and hyperinflammation in pediatric COVID-19: Version 3. Arthritis Rheumatol 2022; 73:e13–29.

These living guidelines created by a multidisciplinary task force establish best practices for the diagnosis and management of patients with MIS-C. The guidelines include recommendations regarding aspirin therapy and anticoagulation.

52. Flood SM, Osborne CM, Martin B, et al. Severe SARS-CoV-2 infection in a pediatric patient requiring extracorporeal membrane oxygenation. Case Rep Pediatr 2020; 2020:8885022.

53. Saeed A, Sharafa E. Status epilepticus as a first presentation of COVID-19 infection in a 3 years old boy; case report and review the literature. ICDCases 2020; 22:e00942.

54. Miller J, Cantor A, Zachariah P, et al. GI symptoms as a major presentation of multisystem inflammatory syndrome in children due to Covid-19. Gastroenterology 2020; 159:1571–1574.

55. Schneider CW, Penney SW, Helfrich AM, et al. A novel use of rifampicin for SARS-CoV-2-induced thrombocytopenia. J Pediatr Hematol Oncol 2021; 43: e788–e790.

56. Wójcieszowska M, Renke J, Igra-Jaworska N. COVID-19 related gastrointestinal bleeding in a pediatric patient with ALL. J Pediatr Hematol Oncol 2021; 44:e543–e545.

57. Malgrange B, Clauberg P, et al. American Society of Hematology 2018 Guidelines for management of venous thrombosis: treatment of pediatric venous thromboembolism: Blood Adv 2018; 2:3292–3316.

58. Goldenberg NA, Kittleton JM, et al. Effect of anticoagulant therapy for 6 weeks vs 3 months on recurrence and bleeding events in patients younger than 21 years of age with provoked venous thromboembolism. JAMA 2022; 327:129.

Goldenberg et al. published the first randomized clinical trial to demonstrate that 6 weeks of anticoagulation is noninferior to 3 months of treatment for provoked thrombosis in pediatric patients.

59. Kaptein FH, Stals MAM, Huisman MV, Klik FA. Prophylaxis and treatment of COVID-19 related venous thromboembolism. Postgrad Med 2021; 133 (Suppl 1):7–35.